Cite
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.
MLA
Vascotto, Fulvia, et al. “Intravenous Delivery of the Toll-like Receptor 7 Agonist SC1 Confers Tumor Control by Inducing a CD8+ T Cell Response.” Oncoimmunology, vol. 8, no. 7, Apr. 2019, p. 1601480. EBSCOhost, https://doi.org/10.1080/2162402X.2019.1601480.
APA
Vascotto, F., Petschenka, J., Walzer, K. C., Vormehr, M., Brkic, M., Strobl, S., Rösemann, R., Diken, M., Kreiter, S., Türeci, Ö., & Sahin, U. (2019). Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. Oncoimmunology, 8(7), 1601480. https://doi.org/10.1080/2162402X.2019.1601480
Chicago
Vascotto, Fulvia, Jutta Petschenka, Kerstin C Walzer, Mathias Vormehr, Magdalena Brkic, Stefan Strobl, Roman Rösemann, et al. 2019. “Intravenous Delivery of the Toll-like Receptor 7 Agonist SC1 Confers Tumor Control by Inducing a CD8+ T Cell Response.” Oncoimmunology 8 (7): 1601480. doi:10.1080/2162402X.2019.1601480.